1-MNA
CAS 1005-24-9
Dry-Basis Assay≥98.5% (dried basis)
Nicotinamide metabolite salt for analytical and biochemical research
1-Methylnicotinamide Chloride (CAS 1005-24-9), specification ≥98.5% (dried basis). Crystalline 1-MNA chloride with assay stated on a dried basis, supplied in 10 kg bags. Batch COA is available. NAD+ ingredients
Quote / sample & delivery
Key Specifications
| Product Positioning | Nicotinamide metabolite salt for analytical and biochemical research |
| Application Scenarios | nicotinamide-metabolite assays · vascular-biology research · analytical reference development |
| CAS Number | 1005-24-9 |
| Dry-Basis Assay | ≥98.5% (dried basis) |
| Molecular Formula | C7H9N2OCl |
| Molecular Weight | 172.6 g/mol |
| Appearance | White to off-white crystalline solid |
| Solubility | Soluble in water and methanol |
| Storage | Store in a well-closed and dry place at room temperature, away from direct sunlight. |
| Shelf Life | 24 months |
Procurement & delivery
Supply details confirmed by intended use, volume and target market
1-Methylnicotinamide chloride (1-MNA, CAS 1005-24-9) is a defined nicotinamide derivative supplied as a crystalline chloride salt. The referenced batch is documented by HPLC assay, identity, water, impurities, residual solvent and microbiological testing for formulation and research qualification.
99.5% HPLC Assay in the Referenced Batch
The referenced batch PGMNC-260718 reports 99.5% assay by HPLC on a dried basis against a 98.5%–101.5% specification.
Ingredient Identity
Crystalline 1-MNA chloride with assay stated on a dried basis, supplied in 10 kg bags.
Batch Quality Profile
The referenced COA records identity, water, loss on drying, heavy metals, impurities, residual solvent and microbiological checks.
Test items, specifications and results for the listed batch are shown here. View or request a COA in the quality documents section.
Batch No.
PGMNC-260718
Test date
2026-07-18
Specification
In-house
Pack size
10 kg/bag
Storage
Store in a well-closed and dry place at room temperature, away from direct sunlight.
Conclusion
Conforms
| Test Item | Specification | Result |
|---|---|---|
| Appearance | White to off-white crystalline solid | Conforms |
| Identification | ¹H NMR confirms structure | Conforms |
| Solubility | Soluble in water and methanol | Conforms |
| Assay (HPLC, dry basis) | 98.5%–101.5% | 99.5% |
| Loss on drying | ≤1.0% | 0.16% |
| Water | ≤0.3% | 0.11% |
| Residue on ignition | ≤0.1% | 0.03% |
| Heavy metals | ≤20 ppm | ≤10 ppm |
| Trigonelline | ≤0.05% | Not detected |
| Nicotinic acid | ≤0.10% | Not detected |
| Nicotinamide | ≤0.10% | Not detected |
| Largest unknown impurity | ≤0.05% | 0.01% |
| Total unknown impurities | ≤0.20% | 0.01% |
| Total impurities | ≤0.50% | 0.01% |
| Residual methanol | ≤0.3% | 0.028% |
| Total plate count | ≤100 CFU/g | ≤10 CFU/g |
| Yeasts and moulds | ≤10 CFU/g | ≤10 CFU/g |
| Pathogens | Absence in 1 g | Not detected |
Request a reviewed COA through the quality documents section and confirm its product form and batch.
Hard capsules
1-MNA chloride is distinct from nicotinamide and NR; convert dried-basis assay to loading on the supplied basis where needed.
99.5%
Assay (HPLC, dry basis)
0.11%
Water
0.01%
Largest unknown impurity
PGMNC-260718 · Results apply to this lot; interpret purity, assay and water on their respective bases.
Composition candidates, processing sequences and tests support pilot design. Confirm candidate excipients and processes using this material in the actual finished formulation.
Study combinations, individual-ingredient mechanisms and product precedents are distinguished; expand each entry for scope and pilot-development checks.
A single-ingredient hard capsule matches an established commercial format and avoids implying an unverified synergistic pairing.
Expand research and formulation notes +Collapse research and formulation notes −Development rationale: A single-ingredient hard capsule matches an established commercial format and avoids implying an unverified synergistic pairing.
Evidence scope: Commercial-format evidence: Endotelio markets a vegan capsule containing 29 mg of 1-MNA. Finished-product dose and eligibility remain market-specific.
Pilot checks: Retain individual-ingredient, blend and carrier controls; check uniformity and post-process assays before packaged samples, documenting study formulations separately from new candidates.
View original research or document ↗Literature-Supported Research Directions
N¹-Methylnicotinamide (MNAM) is generated when nicotinamide is methylated by NNMT. It is a downstream metabolite connected to nicotinamide clearance, one-carbon metabolism and NAD⁺ salvage-pathway balance; it should not be described as a direct NAD⁺ precursor.
Citation: Covarrubias et al. NAD+ metabolism and its roles in cellular processes during ageing. Nature reviews. Molecular cell biology (2021). PMID: 33353981.View source
In a human vascular study, oral MNAM increased brachial-artery flow-mediated dilation and enhanced NO release from cultured human endothelial cells. This supports research into endothelial redox balance, eNOS function and vascular responsiveness.
Citation: Domagala et al. Nitric oxide production and endothelium-dependent vasorelaxation ameliorated by N1-methylnicotinamide in human blood vessels. Hypertension (Dallas, Tex. : 1979) (2012). PMID: 22353616.View source
Preclinical studies associate MNAM with prostacyclin- and NO-dependent endothelial signaling, lower platelet activation and reduced inflammatory burden in atherosclerosis models. These are model-based research findings, not a clinical antithrombotic indication.
Citation: Mateuszuk et al. Antiatherosclerotic Effects of 1-Methylnicotinamide in Apolipoprotein E/Low-Density Lipoprotein Receptor-Deficient Mice: A Comparison with Nicotinic Acid. The Journal of pharmacology and experimental therapeutics (2016). PMID: 26631491.View source
Note: For ingredient R&D and scientific information; findings depend on model, dose, formulation and population and do not constitute a treatment claim or efficacy guarantee.
Lead Time
3–5business days
Standard products are generally in stock; confirm the exact lead time with us.
Minimum Order
Contact us
Samples, pilot trials, and commercial volumes are supported.
Foil Pouch
Sealed, moisture-protective inner packaging
Fiber Drum
Standard outer packaging for bulk transport
Bulk Shipping
Palletized and stretch-wrapped for protection
Ambient storage: foil pouch + fiber drum; temperature controlled: foil pouch + insulated box/carton. Confirm by product.
Custom packaging: Custom foil bags or HDPE drums, GMP label printing, and export documentation are available. Contact us for a quote.Images are packaging illustrations.
Certifications
Assay/purity is reported against the referenced batch COA; request the current lot documentation before qualification.
A marketed single-ingredient hard-capsule format is available. Confirm capsule-shell compatibility, moisture control, serving level, target-market authorization and label restrictions before scale-up.
1-Methylnicotinamide chloride (1-MNA) is a nicotinamide derivative supplied as a crystalline chloride salt, CAS 1005-24-9, formula C7H9N2OCl and molecular weight 172.6 g/mol. COA PGMNC-260718 includes 1H NMR identification.
The referenced batch PGMNC-260718 reports 99.5% assay by HPLC on the dried basis. The specification range is 98.5%–101.5% on the dried basis.
The COA checks trigonelline, nicotinic acid, nicotinamide, unknown impurities, total impurities and residual methanol. The referenced batch reports total impurities of 0.01% and residual methanol of 0.028%.
1-Methylnicotinamide chloride is soluble in water and methanol, as described in COA PGMNC-260718. Test compatibility at the intended concentration, pH and excipient system before scale-up.
1-Methylnicotinamide chloride is packaged in 10 kg bags. Store well closed and dry at room temperature, protected from direct sunlight. Use the supplied lot label and documents for the applicable expiry date.
1-MNA supplier qualification can use the specification, offered lot COA and applicable SDS/TDS. Review identity, dry-basis assay, impurities and microbiological requirements against the agreed testing scope. Historical lot results are references, not substitutes for offered-lot documentation.
Documents are subject to product and batch availability; third-party reports are provided only when applicable.
Quality documents
The specification sheet defines acceptance limits. The COA shows actual batch results, which may vary by batch. Third-party reports are provided only for products or batches that have been independently tested.
Stable acceptance criteria · Available on request
Actual test data · Check the COA for the applicable batch
Related Products
NMN Powder (β-Nicotinamide Mononucleotide)
β-Nicotinamide Adenine Dinucleotide Powder
Nicotinamide Riboside Chloride Powder
Nicotinamide Riboside Hydrogen Malate Powder
Interested in 1-MNA?
Our R&D team will respond to your inquiry or sample request within 24 hours.
Scan to add WeChat
Alex Huang · Mon–Fri 9am–6pm CST
